diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5498diaendo-5498Research ArticleСтатьиArticlesСосудистые осложнения сахарного диабета 2 типа за гранью гликемического контроляVascular complications of type 2 diabetes mellitus beyond the reach of glycemic controlДемидоваТатьяна ЮльевнаDemidovaTatiana Yul'evnat.y.demidova@gmail.ruГОУ ДПО Российская медицинская академия последипломного образования, Москва201015092010133№3 (2010)111116Copyright © Демидова Т.Ю., 20102010Демидова Т.Ю.Demidova T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5498

Современная стратегия управления сахарного диабета 2 типа ставит задачу сокращения риска развития острых и отдаленных сосу-дистых нарушений как следствие достижения целевых уровней нормогликемии, улучшения качества и продолжительности жизни па-циентов, а также минимизации социально-экономических потерь. Помимо хорошего гликемического контроля, необходим скрининги лечение факторов сердечно-сосудистого риска, т.к. может помочь предотвратить или отсрочить на длительное время развитиемакрососудистых осложнений.

Current therapeutic strategies of type 2 diabetes mellitus are aimed at reducing the risk of acute and late vascular complications by means of normalizationof glycemia, improvement of life quality and expectancy, minimization of socio-economic losses. The adequate glycemic control should besupplemented by screening for and correction of risk factors of cardiovascular disorders; it may help to prevent or delay the development of macrovascularcomplications.

сахарный диабетсосудистые осложнениягликемический контрольReferencesGaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2003. - 348. - Р. 383-393 and 358. - Р. 580-591, 2008.Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2003. - 348. - Р. 383-393 and 358. - Р. 580-591, 2008.Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2008. - 358. - Р. 580-591.Gaede P., Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular disease in people with type 2 diabetes // New England Journal of Medicine. - 2008. - 358. - Р. 580-591.Brownlee M. Biochemistry and molecular cell biology of diabetic complications // Nature. - 2001. - 414. - Р. 813-820.Brownlee M. Biochemistry and molecular cell biology of diabetic complications // Nature. - 2001. - 414. - Р. 813-820.Caballero A.E. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease // Obesity Research. - 2003. - Vol. 11(11). - Р. 1278-1289.Caballero A.E. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease // Obesity Research. - 2003. - Vol. 11(11). - Р. 1278-1289.The ACCORD Study Group and 1. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes // N. Engl. J. Med. - 2010. - DOI: 10.1056/NEJMoa1001288.The ACCORD Study Group and 1. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes // N. Engl. J. Med. - 2010. - DOI: 10.1056/NEJMoa1001288.ACCORD Study Group // N. Engl. J. Med. - 2010. - March. 14.ACCORD Study Group // N. Engl. J. Med. - 2010. - March. 14.Beulens J.W., Patel A., Vingerling J.R., et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial // Diabetologia. - 2009. - 52. - Р. 2027-2036.Beulens J.W., Patel A., Vingerling J.R., et al. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial // Diabetologia. - 2009. - 52. - Р. 2027-2036.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - Р. 837-853. (Erratum, Lancet 1999; 354: 602.)UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. - 1998. - 352. - Р. 837-853. (Erratum, Lancet 1999; 354: 602.)UK Prospective Diabetes Study (UKPDS) Group. Effects of blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34) // Lancet. - 1998. - 352 (9131). - Р. 854-865.UK Prospective Diabetes Study (UKPDS) Group. Effects of blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34) // Lancet. - 1998. - 352 (9131). - Р. 854-865.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38) // British Medical Journal. - 1998. - 317. - Р. 703-713.UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38) // British Medical Journal. - 1998. - 317. - Р. 703-713.Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials // BMJ. - 2006. - May 13, 332. - Р. 1115-1124.Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials // BMJ. - 2006. - May 13, 332. - Р. 1115-1124.American Diabetes Association. Standards of Medical Care in Diabetes: Dislipidemia Management // Diabetes Care. - 2007. - 30 (Suppl 1). - S4-S41.American Diabetes Association. Standards of Medical Care in Diabetes: Dislipidemia Management // Diabetes Care. - 2007. - 30 (Suppl 1). - S4-S41.Irons B.K., Kroon L.A. Lipid Management with Statins in Type 2 Diabetes Mellitus. The Annals of Pharmacotherapy. - 2005. - 39, № 10. - Р. 1714-1718.Irons B.K., Kroon L.A. Lipid Management with Statins in Type 2 Diabetes Mellitus. The Annals of Pharmacotherapy. - 2005. - 39, № 10. - Р. 1714-1718.Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians // Ann Intern. Med. - 2004. - 140. - Р. 644-649.Snow V., Aronson M.D., Hornbake E.R., Mottur-Pilson C., Weiss K.B. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians // Ann Intern. Med. - 2004. - 140. - Р. 644-649.Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate // Am. J. Cardiol. - 2008. - 102(12A). - 34L-40L.Sacks F.M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate // Am. J. Cardiol. - 2008. - 102(12A). - 34L-40L.Keech A.C., Mitchell P., Summanen P.A. et al., for the FIELD study investiga- tors. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial // Lancet. - 2007. - 370 (9600). - P.1687-1697.Keech A.C., Mitchell P., Summanen P.A. et al., for the FIELD study investiga- tors. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial // Lancet. - 2007. - 370 (9600). - P.1687-1697.Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR . agonist, in traumatic brain injury // J. Neurotrauma. - 2007. - 24. - Р. 1119-1131.Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR . agonist, in traumatic brain injury // J. Neurotrauma. - 2007. - 24. - Р. 1119-1131.Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR. agonist, in traumatic brain injury // Diabetes care. - 2009. - vol. 32, № 8, august.Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and antioxidative effects afforded by fenofibrate, a PPAR. agonist, in traumatic brain injury // Diabetes care. - 2009. - vol. 32, № 8, august.Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., Drury P., Kesaniemi Y.A., Sullivan D., Hunt D., Colman P., d'Emden M., Whiting M., Ehnholm C., Laakso M.; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.Kushwin Rajamani, Peter G. Colman, Li Ping Li, James D. Best, Merryn Voysey, Michael C. D'Emden, Markku Laakso, John R. Baker, Anthony C. Keech, on behalf of the FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trialKushwin Rajamani, Peter G. Colman, Li Ping Li, James D. Best, Merryn Voysey, Michael C. D'Emden, Markku Laakso, John R. Baker, Anthony C. Keech, on behalf of the FIELD study investigators Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trialSergio Fazio Cardiovasc Drugs Ther June 2009.Vol 23(3):235-241Sergio Fazio Cardiovasc Drugs Ther June 2009.Vol 23(3):235-241Rajamani K et al. Lancet. 2009;373:1780-8Rajamani K et al. Lancet. 2009;373:1780-8IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.IDF Clinical Guidelines Task Force. Global guideline for Type 2 diabetes. Brussels: International Diabetes Federation, 2005.ESC/EASD Guidelines. Eur Heart J 2007; P. 28:88-136.ESC/EASD Guidelines. Eur Heart J 2007; P. 28:88-136.Home P et al. BMJ 2008; 336; P. 1306-8.Home P et al. BMJ 2008; 336; P. 1306-8.American Diabetes Association. Diabetes Care. 2008;31(suppl 1): S12-S54.American Diabetes Association. Diabetes Care. 2008;31(suppl 1): S12-S54.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106: P. 3143-421.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002; 106: P. 3143-421.

The authors declare that there are no conflicts of interest present.